Evidence map›Paper›PMID 34360581›Full record

ArticleInternational journal of molecular sciences2021

The Slow-Releasing and Mitochondria-Targeted Hydrogen Sulfide (H

Bartosz Pomierny, Weronika Krzyżanowska, Jakub Jurczyk, Alicja Skórkowska, Beata Strach, Małgorzata Szafarz, Katarzyna Przejczowska-Pomierny, Roberta Torregrossa, Matthew Whiteman, Monika Marcinkowska and 2 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Black gas, bright future: HNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Bartosz PomiernyDepartment of Toxicological Biochemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland.ORCID 0000-0002-5352-5324
Weronika KrzyżanowskaDepartment of Toxicological Biochemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland.
Jakub JurczykDepartment of Toxicological Biochemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland.
Alicja SkórkowskaDepartment of Toxicological Biochemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland.
Beata StrachDepartment of Neurology, Faculty of Medicine, Jagiellonian University Medical College, Botaniczna 3, 31-503 Kraków, Poland.
Małgorzata SzafarzDepartment of Pharmacokinetics and Physical Pharmacy, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland.
Katarzyna Przejczowska-PomiernyDepartment of Pharmacokinetics and Physical Pharmacy, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland.ORCID 0000-0001-9833-5885
Roberta TorregrossaSt. Luke's Campus, University of Exeter Medical School, Exeter EX1 2LU, UK.
Matthew WhitemanSt. Luke's Campus, University of Exeter Medical School, Exeter EX1 2LU, UK.
Monika MarcinkowskaDepartment of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland.ORCID 0000-0002-4948-6617
Joanna PeraDepartment of Neurology, Faculty of Medicine, Jagiellonian University Medical College, Botaniczna 3, 31-503 Kraków, Poland.ORCID 0000-0001-6142-2969
Bogusława BudziszewskaDepartment of Toxicological Biochemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland.
Jagiellonian University · PLUniversity of Exeter · GB

Funding

Medical Research Council MR/S002626/1Narodowe Centrum Nauki 2016/21/D/NZ4/03302
6 · The paper itself

Abstract

Ischemic stroke is the third leading cause of death in the world, which accounts for almost 12% of the total deaths worldwide. Despite decades of research, the available and effective pharmacotherapy is limited. Some evidence underlines the beneficial properties of hydrogen sulfide (H

Indexed as

AnimalsBrain IschemiaHydrogen SulfideInfarction, Middle Cerebral ArteryMaleMitochondriaOrganophosphorus CompoundsProtective AgentsRatsRats, Sprague-DawleyThionesAP39 compoundHydrogen SulfideOrganophosphorus CompoundsProtective AgentsThionesAP39brain ischemiabrain preconditioninghydrogen sulfidemitochondrial targetingneuroinflammation

Identifiers

PMID34360581
PMCPMC8346077
OpenAlexW3186010932

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.